FMP

FMP

Enter

ATOS - Atossa Therapeutics, Inc.

Profile of Atossa Therapeutics, Inc.(ATOS), Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and

About

ceo

Dr. Steven C. Quay FCAP, M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.atossatherapeutics.com

exchange

NASDAQ

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

CIK

0001488039

ISIN

US04962H5063

CUSIP

04962H506

Address

107 Spring Street

Phone

206 588 0256

Country

US

Employee

11

IPO Date

Nov 8, 2012

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep